

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Patient preferred clinic:	<input type="checkbox"/> Order Renewal

Phone: 1-800-809-1265 Fax: 1-866-872-8920

Skyrizi® (risankizumab-rzaa) Standard Plan of Treatment for Ulcerative Colitis

Rev 4.28.25

PATIENT DEMOGRAPHICS:

Patient Name:	
Patient's Phone:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG Gender:
	Allergies:
	<input type="checkbox"/> See list <input type="checkbox"/> NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

K51.0 Ulcerative (Chronic) Pancolitis	K51.4 Inflammatory Polyps of Colon
K51.2 Ulcerative (Chronic) Proctitis	K51.5 Left Sided Colitis
K51.3 Ulcerative (Chronic) Rectosigmoiditis	K51.8 Other Ulcerative Colitis or Unspecified
- Other:	

REQUESTED DOCUMENTATION:
PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

1 Insurance information	IF NO:	IF YES:
2 Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3 Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4 Tried and failed therapies	FROM PREVIOUS	IF ORDER CHANGE:
5 REQUIRED: TB screening for new start	THERAPY:	
6 Baseline LFTs and bilirubin level		
		Continue current order until insurance approved

AMBULATORY INFUSION MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive risankizumab-rzaa if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, and/or surgery.

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

IV	Diphenhydramine	25mg	50mg	PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg		Other:	Famotidine	20mg	40mg	
	Famotidine	20mg	40 mg			Diphenhydramine	25mg	50mg	
	Other:					Fexofenadine	60mg	180mg	
						Cetirizine	10mg		
					Loratadine	10mg			
					Other:				

INDUCTION DOSE:
 Skyrizi® (risankizumab-rzaa) 1200mg in 250ml-500ml of NS given IV over at least 2 hours

IV-FREQUENCY:
 Week 0, week 4, and week 8
 Other:

SPECIAL/OTHER LAB ORDERS:

IN HOME/SPECIALTY PHARMACY ORDERS:
MAINTENANCE DOSE:
 Skyrizi® (risankizumab-rzaa) 180mg given subcutaneously
 Skyrizi® (risankizumab-rzaa) 360mg given subcutaneously

FREQUENCY:
 At week 12 and then every 8 weeks thereafter
 Other:

Some commercial insurance plans require maintenance doses to be provided by the plan's specialty pharmacy. Providers will be notified if Palmetto Infusion cannot dispense the maintenance doses due to plan restrictions or patient preference.

 Refills x 12 months unless noted otherwise here:

NURSING ORDERS:

- Start PIV/Access CVC.
- Flush device per facility standard flushing procedure.
- Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated.
- In Home Supply orders: All supplies for drug administration and adverse reaction kit for in home use will be provided.

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion AIC standing adverse reaction orders. Home Standing orders including Home Anaphylaxis Kit dispense as written and administer for mild and severe reaction are provided

PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures)
DATE:

Dispense as written/Brand medically necessary	Substitution permitted